Pacira BioSciences (PCRX) Competitors $21.59 -0.70 (-3.14%) Closing price 04:00 PM EasternExtended Trading$21.58 0.00 (-0.02%) As of 07:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock PCRX vs. PRGO, SUPN, NKTR, OMER, ASMB, CPIX, LLY, JNJ, ABBV, and MRKShould you be buying Pacira BioSciences stock or one of its competitors? The main competitors of Pacira BioSciences include Perrigo (PRGO), Supernus Pharmaceuticals (SUPN), Nektar Therapeutics (NKTR), Omeros (OMER), Assembly Biosciences (ASMB), Cumberland Pharmaceuticals (CPIX), Eli Lilly and Company (LLY), Johnson & Johnson (JNJ), AbbVie (ABBV), and Merck & Co., Inc. (MRK). These companies are all part of the "pharmaceuticals" industry. Pacira BioSciences vs. Its Competitors Perrigo Supernus Pharmaceuticals Nektar Therapeutics Omeros Assembly Biosciences Cumberland Pharmaceuticals Eli Lilly and Company Johnson & Johnson AbbVie Merck & Co., Inc. Pacira BioSciences (NASDAQ:PCRX) and Perrigo (NYSE:PRGO) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, analyst recommendations, valuation, media sentiment and institutional ownership. Which has better valuation and earnings, PCRX or PRGO? Pacira BioSciences has higher earnings, but lower revenue than Perrigo. Perrigo is trading at a lower price-to-earnings ratio than Pacira BioSciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPacira BioSciences$700.97M1.43-$99.56M-$2.28-9.47Perrigo$4.37B0.85-$171.80M-$1.31-20.57 Does the media favor PCRX or PRGO? In the previous week, Perrigo had 2 more articles in the media than Pacira BioSciences. MarketBeat recorded 5 mentions for Perrigo and 3 mentions for Pacira BioSciences. Perrigo's average media sentiment score of 1.14 beat Pacira BioSciences' score of 0.66 indicating that Perrigo is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pacira BioSciences 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Perrigo 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders & institutionals have more ownership in PCRX or PRGO? 99.7% of Pacira BioSciences shares are owned by institutional investors. Comparatively, 95.9% of Perrigo shares are owned by institutional investors. 6.4% of Pacira BioSciences shares are owned by company insiders. Comparatively, 0.7% of Perrigo shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Do analysts prefer PCRX or PRGO? Pacira BioSciences currently has a consensus price target of $26.44, indicating a potential upside of 22.48%. Perrigo has a consensus price target of $33.00, indicating a potential upside of 22.45%. Given Pacira BioSciences' stronger consensus rating and higher possible upside, analysts clearly believe Pacira BioSciences is more favorable than Perrigo.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pacira BioSciences 1 Sell rating(s) 4 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.33Perrigo 0 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.25 Which has more risk and volatility, PCRX or PRGO? Pacira BioSciences has a beta of 0.48, meaning that its stock price is 52% less volatile than the S&P 500. Comparatively, Perrigo has a beta of 0.45, meaning that its stock price is 55% less volatile than the S&P 500. Is PCRX or PRGO more profitable? Perrigo has a net margin of -4.16% compared to Pacira BioSciences' net margin of -14.78%. Pacira BioSciences' return on equity of 13.78% beat Perrigo's return on equity.Company Net Margins Return on Equity Return on Assets Pacira BioSciences-14.78% 13.78% 7.00% Perrigo -4.16%8.93%3.87% SummaryPacira BioSciences beats Perrigo on 11 of the 16 factors compared between the two stocks. Get Pacira BioSciences News Delivered to You Automatically Sign up to receive the latest news and ratings for PCRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PCRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PCRX vs. The Competition Export to ExcelMetricPacira BioSciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.03B$2.96B$5.54B$9.41BDividend YieldN/A2.46%3.75%4.03%P/E Ratio-9.478.2821.0120.09Price / Sales1.43303.17433.8199.01Price / Cash5.1642.5936.1658.27Price / Book1.287.678.125.65Net Income-$99.56M-$55.28M$3.25B$257.91M7 Day Performance-5.72%2.50%0.97%2.09%1 Month Performance-10.60%11.70%7.36%11.13%1 Year Performance6.78%4.89%31.31%18.40% Pacira BioSciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PCRXPacira BioSciences3.1024 of 5 stars$21.59-3.1%$26.44+22.5%+6.2%$1.03B$700.97M-9.47720PRGOPerrigo4.6253 of 5 stars$26.74-1.7%$33.00+23.4%-2.0%$3.74B$4.37B-20.418,379News CoveragePositive NewsSUPNSupernus Pharmaceuticals2.3694 of 5 stars$31.45-1.7%$36.00+14.5%+16.0%$1.79B$661.82M28.33580Positive NewsNKTRNektar Therapeutics4.0678 of 5 stars$23.47-5.2%$84.17+258.6%+22.6%$307.20M$98.43M-2.45220Analyst RevisionHigh Trading VolumeOMEROmeros3.7837 of 5 stars$3.08-3.8%$18.00+484.4%-33.1%$187.50MN/A-1.16210Positive NewsAnalyst RevisionGap UpASMBAssembly Biosciences3.7919 of 5 stars$18.56+2.3%$33.00+77.8%+27.1%$138.54M$28.52M-2.98100Trending NewsCPIXCumberland Pharmaceuticals0.8866 of 5 stars$3.04-3.5%N/A+152.4%$47.13M$37.87M-12.1680Trending NewsLLYEli Lilly and Company4.979 of 5 stars$772.82-1.0%$1,011.61+30.9%-15.8%$739.87B$45.04B62.8847,000Trending NewsJNJJohnson & Johnson4.7823 of 5 stars$155.23-0.5%$170.88+10.1%+4.1%$375.37B$88.82B17.27138,100Trending NewsEarnings ReportDividend AnnouncementAnalyst ForecastOptions VolumeAnalyst RevisionABBVAbbVie4.7838 of 5 stars$187.44-1.0%$211.29+12.7%+9.1%$334.34B$56.33B79.7655,000Trending NewsEx-DividendAnalyst RevisionMRKMerck & Co., Inc.4.9955 of 5 stars$80.890.0%$109.19+35.0%-35.2%$203.22B$64.17B11.7775,000Positive News Related Companies and Tools Related Companies Perrigo Competitors Supernus Pharmaceuticals Competitors Nektar Therapeutics Competitors Omeros Competitors Assembly Biosciences Competitors Cumberland Pharmaceuticals Competitors Eli Lilly and Company Competitors Johnson & Johnson Competitors AbbVie Competitors Merck & Co., Inc. Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PCRX) was last updated on 7/18/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored[ATTENTION] This Crypto Rocket Is About Launch…Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to tw...Crypto Swap Profits | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredFREE BUY ALERT: These 3 tiny AI stocks could surgeWe're living in unprecedented times. Most people think it's too late to get into AI right now … That the...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pacira BioSciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pacira BioSciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PCRX Stock Alerts